loading...| Preferred Name |
flutamide |
|
| Synonyms |
Grisetin |
|
| Definitions |
A toluidine derivative and nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C509" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C509" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000039811 |
|
| altLabel |
Grisetin Cytomid Prostacur Prostica Flutaplex Testotard Euflex Flucinome Flucinom Fluken Flulem Profamid Fluta-Gry Tecnoflut Chimax Drogenil Flugerel Flutacan Cebatrol 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide FLUT Flutabene Sch 13521 4'-nitro-3'-trifluoromethylisobutyranilide Flutamex Niftolide Tafenil Fugerel alpha,alpha,alpha-trifluoro-2-methy-4'-nitro-m-propionotoluidide Flutan Oncosal Prostadirex Flutamin Prostogenat Apimid Eulexine |
|
| CAS Registry |
13311-84-7 |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000041483 http://purl.bioontology.org/ontology/PDQ/CDR0000041292 http://purl.bioontology.org/ontology/PDQ/CDR0000041183 http://purl.bioontology.org/ontology/PDQ/CDR0000363905 http://purl.bioontology.org/ontology/PDQ/CDR0000410698 http://purl.bioontology.org/ontology/PDQ/CDR0000042912 http://purl.bioontology.org/ontology/PDQ/CDR0000041521 http://purl.bioontology.org/ontology/PDQ/CDR0000041518 http://purl.bioontology.org/ontology/PDQ/CDR0000038845 http://purl.bioontology.org/ontology/PDQ/CDR0000041522 http://purl.bioontology.org/ontology/PDQ/CDR0000038349 http://purl.bioontology.org/ontology/PDQ/CDR0000041519 http://purl.bioontology.org/ontology/PDQ/CDR0000042084 http://purl.bioontology.org/ontology/PDQ/CDR0000043049 http://purl.bioontology.org/ontology/PDQ/CDR0000358199 http://purl.bioontology.org/ontology/PDQ/CDR0000410697 http://purl.bioontology.org/ontology/PDQ/CDR0000043340 |
|
| cui |
C1517262 C1517258 C1517265 C0591412 C1517248 C1517249 C0016384 C1522368 C1517255 C1517254 C1517260 C1517245 C1517267 C3692587 C1517266 C1517261 C0700681 C1517264 C1517259 C1517256 C1517251 C1522370 C1517263 C1517252 C1517250 C0595574 C4053710 C1517257 C1517253 |
|
| Date last modified |
2015-10-05 |
|
| definition |
A toluidine derivative and nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C509" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C509" NCI Thesaurus) |
|
| IND Code |
25378 |
|
| Legacy PDQ ID |
2488 |
|
| LT |
TRD |
|
| NCI ID |
C509 |
|
| notation |
CDR0000039811 |
|
| NSC Code |
147834 215876 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
flutamide |
|
| tui |
T109 T121 |